Carcinoma, Squamous Cell
Conditions
Keywords
squamous cell carcinoma of the head and neck
Brief summary
The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict response to treatment and survival.
Detailed description
Primary Endpoint To compare the SUV (standardized uptake value) at up to three target tumor sites as assessed by FDG-PET/CT of eligible patients at baseline and then after eight weeks of treatment with cetuximab. Secondary Endpoints * To determine the overall tumor metabolic response (complete metabolic response, partial metabolic response, stable metabolic disease or progressive metabolic disease \[CMR, PMR, SMD, or PMD\]) to eight weeks of scheduled weekly doses of cetuximab as assessed by FDG-PET/CT performed at baseline and then after therapy. * To correlate the overall tumor metabolic response (CMR, PMR, SMD, or PMD) as assessed by FDG-PET/CT with the anatomic tumor response rate (complete response, partial response, stable disease or progressive disease \[CR, PR, SD, or PD\]) by RECIST criteria as assessed by CT and clinical examination performed after eight weeks of scheduled weekly doses of cetuximab. * To correlate the overall tumor metabolic response (CMR, PMR, SMD, or PMD) as assessed by FDG-PET/CT and to correlate the overall anatomic tumor response (CR, PR, SD, or PD) by RECIST criteria as assessed by CT and clinical examination obtained at baseline and after eight weeks of treatment with weekly scheduled doses of cetuximab to TTP (time to progression) and OS (overall survival) with cetuximab therapy. * To determine the overall best anatomic tumor response rate (CR, PR, SD, or PD) to cetuximab given until disease progression as assessed by RECIST criteria using CT and clinical examination. * To determine the overall disease control rate (CR, PR, and SD) by RECIST criteria as assessed by CT and clinical examination and to determine the TTP and the OS with cetuximab therapy. * To assess the toxicity profile for standard of care cetuximab given to patients with metastatic squamous cell carcinoma of the head and neck.
Interventions
PROCEDUREFDG-PET/CT
DRUGCetuximab
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven diagnosis of squamous cell carcinoma of the head and neck (SCCHN). * Have either locally recurrent, unresectable, previously irradiated SCCHN OR metastatic SCCHN, with at least one measurable tumor lesion (by CT scan) and at least one FDG avid (SUV \>/= 3, \>/= 1.5 cm) tumor lesion (by PET/CT). * Age greater than 18 yrs. * ECOG Performance Status of 0-3 * Signed IRB approved Informed Consent.
Exclusion criteria
* Clinical history of severe interstitial lung disease (not COPD)-as defined by prior pulmonary function tests (PFTs) with residual volume, total lung capacity, or corrected diffuse lung capacity for carbon monoxide (DLCO) \<30% of predicted. For this study, screening PFT's required only if clinically indicated. * Prior therapy with an epidermal growth factor receptor (EGFR)-specific monoclonal antibody (MAB) for treatment of metastatic SCCHN. Prior therapy with an EGFR-specific MAB as part of the definitive treatment of non-metastatic SCCHN is acceptable if this occurred more than three months previously. Prior therapy with an EGFR specific TKI will not be an exclusion factor. * Women of child bearing potential who are current pregnant or breast feeding. * Prior severe (Grade 4) infusion reaction to cetuximab. * A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy. * Chemotherapy, radiation therapy, or investigational agents given with the last 14 days. * Uncontrolled diabetes mellitus. (Subjects with a fasting blood glucose \> 200 at time of PET scanning may need to reschedule to another day after consulting with appropriate physicians.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT | Baseline and after 8 weeks of treatment | FDG-PET/CT images were evaluated qualitatively as well as quantitatively by one of two experienced nuclear radiologists. For quantitative analysis, SUVmax within each of the metastatic tumor sites was determined within a volume of interest around the tumor using a Siemens eSoft workstation. Up to a maximum of three target lesions(\>= 1.5 cm on the baseline CT) were identified as target lesions on the baseline FDG-PET. When multiple lesions were present, those having the greatest FDG uptake on the baseline FDG-PET were selected as target lesions. Lesions containing areas of necrosis were avoided. Other metabolically active lesions and lesions that were \<1.5 cm on CT were considered non-target lesions. When more than one target lesion was identified, the average percentage change in SUVmax was used to determine metabolic response. |
| SUVmax at up to Three Target Tumor Sites as Assessed by FDG-PET/CT of Eligible Patients at Baseline and Then After Eight Weeks of Treatment With Cetuximab. | Baseline and after 8 weeks of treatment | Eight weeks of treatment is equal to one cycle of treatment. FDG-PET/CT images were evaluated qualitatively as well as quantitatively by one of two experienced nuclear radiologists. For quantitative analysis, SUVmax within each of the metastatic tumor sites was determined within a volume of interest around the tumor using a Siemens eSoft workstation. Up to a maximum of three target lesions(\>= 1.5 cm on the baseline CT) were identified as target lesions on the baseline FDG-PET. When multiple lesions were present, those having the greatest FDG uptake on the baseline FDG-PET were selected as target lesions. Lesions containing areas of necrosis were avoided. Other metabolically active lesions and lesions that were \<1.5 cm on CT were considered non-target lesions. When more than one target lesion was identified, the average percentage change in SUVmax was used to determine metabolic response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | After 8 weeks of treatment | A generalization of McNemar's test was used to test for concordance of response(partial, stable or progression) by CT and by FDG-PET/CT. |
| Determine the Overall Disease Control Rate by RECIST Criteria as Assessed by CT and Clinical Examination and to Determine the TTP and the OS With Cetuximab Therapy | Every 8 weeks until death (approximately 5 years) | — |
| Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Overall Survival With Cetuximab Therapy | Every 8 weeks until death (approximately 5 years) | — |
| Overall Tumor Metabolic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by FDG-PET/CT | After 8 weeks of treatment | Definitions of metabolic response by FDG-PET/CT included: complete metabolic response(CMR)-complete resolution of all metabolically active target and non-target lesions, and no new lesions; partial metabolic response(PMR)-20% or greater decrease in SUV of target lesions with or without decrease in number/size of non-target lesions, and no new lesions; progressive metabolic disease(PMD)-one or more new lesions, 20% or greater increase in SUV of target lesions and/or unequivocal increase in FDG activity of non-target lesions; and stable metabolic disease(SMD)-not qualifying as CMR, PMR, or PMD. |
| Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Time to Progression (TTP) With Cetuximab Therapy | Every 8 weeks until disease progression (up to 1 year) | Cetuximab was continued after cycle 1 in patients with disease control(PR/SD) by CT, even if the FDG-PET/CT showed PMD. Cetuximab was discontinued after cycle 1 in patients with progression by CT. |
| Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | 30 days after end of study treatment (approximately 1 year after start of treatment) | — |
| Overall Best Anatomic Tumor Response Rate to Cetuximab Given Until Disease Progression as Assessed by RECIST Criteria Using CT & Clinical Examination | Every 8 weeks until disease progression (up to 1 year) | — |
| Overall Anatomic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by CT Scan | After 8 weeks of treatment | Definitions of anatomic response by RECIST for CT scan included: complete response(CR)-disappearance of all target and non-target lesions and no new lesions; partial response(PR)-at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter, persistence of one or more non-target lesions, and no new lesions; stable disease (SD)-neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter since the treatment started, persistence of one or more non-target lesions, and no new lesions; progressive disease(PD)-at least a 20% increase in the sum of the longest diameter of target lesions recorded since the treatment started, appearance of one or more new lesions/unequivocal progression of existing non-target lesions. |
Countries
United States
Participant flow
Recruitment details
Recruitment was open from 06/03/08-10/17/11 at the Siteman Cancer Center (a medical clinic).
Participants by arm
| Arm | Count |
|---|---|
| Arm 1 (Cetuximab) Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)
Cetuximab 400 mg/m2 IV over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.
Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)
Cetuximab 250 mg/m2 IV over 1 hour on Day 57
Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease | 27 |
| Total | 27 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | Cutaneous SCC of head and neck | 3 |
| Overall Study | Ineligible post-hoc | 1 |
| Overall Study | Progressive disease before C1 week 8 | 8 |
Baseline characteristics
| Characteristic | Arm 1 (Cetuximab) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 14 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants |
| Age, Continuous | 63 years |
| Performance Status Performance Status 0 | 5 participants |
| Performance Status Performance Status 1 | 13 participants |
| Performance Status Performance Status 2 | 9 participants |
| Primary Tumor Site Hypopharynx | 5 participants |
| Primary Tumor Site Larynx | 4 participants |
| Primary Tumor Site Oral cavity | 10 participants |
| Primary Tumor Site Oropharynx | 8 participants |
| Prior Cetuximab Exposure No | 19 participants |
| Prior Cetuximab Exposure Yes | 8 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 23 Participants |
| Region of Enrollment United States | 27 participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 6 Participants |
| Smoking history No | 3 participants |
| Smoking history Yes | 24 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 42 / 42 |
| serious Total, serious adverse events | 7 / 42 |
Outcome results
Primary
Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT
FDG-PET/CT images were evaluated qualitatively as well as quantitatively by one of two experienced nuclear radiologists. For quantitative analysis, SUVmax within each of the metastatic tumor sites was determined within a volume of interest around the tumor using a Siemens eSoft workstation. Up to a maximum of three target lesions(\>= 1.5 cm on the baseline CT) were identified as target lesions on the baseline FDG-PET. When multiple lesions were present, those having the greatest FDG uptake on the baseline FDG-PET were selected as target lesions. Lesions containing areas of necrosis were avoided. Other metabolically active lesions and lesions that were \<1.5 cm on CT were considered non-target lesions. When more than one target lesion was identified, the average percentage change in SUVmax was used to determine metabolic response.
Time frame: Baseline and after 8 weeks of treatment
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Arm 1 (Cetuximab) | Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT | -21 percentage of change |
Primary
SUVmax at up to Three Target Tumor Sites as Assessed by FDG-PET/CT of Eligible Patients at Baseline and Then After Eight Weeks of Treatment With Cetuximab.
Eight weeks of treatment is equal to one cycle of treatment. FDG-PET/CT images were evaluated qualitatively as well as quantitatively by one of two experienced nuclear radiologists. For quantitative analysis, SUVmax within each of the metastatic tumor sites was determined within a volume of interest around the tumor using a Siemens eSoft workstation. Up to a maximum of three target lesions(\>= 1.5 cm on the baseline CT) were identified as target lesions on the baseline FDG-PET. When multiple lesions were present, those having the greatest FDG uptake on the baseline FDG-PET were selected as target lesions. Lesions containing areas of necrosis were avoided. Other metabolically active lesions and lesions that were \<1.5 cm on CT were considered non-target lesions. When more than one target lesion was identified, the average percentage change in SUVmax was used to determine metabolic response.
Time frame: Baseline and after 8 weeks of treatment
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm 1 (Cetuximab) | SUVmax at up to Three Target Tumor Sites as Assessed by FDG-PET/CT of Eligible Patients at Baseline and Then After Eight Weeks of Treatment With Cetuximab. | Pre-Cetuximab | 9.3 SUVmax |
| Arm 1 (Cetuximab) | SUVmax at up to Three Target Tumor Sites as Assessed by FDG-PET/CT of Eligible Patients at Baseline and Then After Eight Weeks of Treatment With Cetuximab. | Post Cycle 1 | 7.3 SUVmax |
Secondary
Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Time frame: 30 days after end of study treatment (approximately 1 year after start of treatment)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Brachial plexophathy | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Mood alteration - anxiety | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Fatigue | 15 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Allergic reaction/hypersensitivity | 5 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hypotension | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | INR | 9 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | PTT | 8 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Fever | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Insomnia | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Rigors | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Weight loss | 7 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Failure to thrive | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Death - progression | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Alopecia | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Bruising - port site | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Bruising - thigh | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Rash/desquamation | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Chelitis | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dry skin | 7 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Rash - acneiform | 28 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Rash - trach site | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Anorexia | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Constipation | 7 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dehydration | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Diarrhea | 5 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dry mouth | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dysphagia | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Mucositis | 4 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Nausea | 13 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Taste alteration | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Vomiting | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hemoglobin | 21 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Leukopenia | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Lymphopenia | 27 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Platelets | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hemorrhage: nose | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hemorrhage: oral cavity | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hemorrhage: pulmonary | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hemorrhage: tumor site | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Alkaline phosphatase | 6 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Bilirubin | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | SGOT (AST) | 6 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | SGPT (ALT) | 9 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection without neutropenia | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - cellulitis | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - left neck wound | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - sinus | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - scalp drainage Ecoli | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - scalp wound | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - skin | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - staph shingles | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - tumor | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - upper respiratory | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - urinary tract infection | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection normal ANC - yeast | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection lung - pneumonia | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Infection skin - ungual | 9 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Edema - eye | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Edema - head & neck | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Edema - limb | 4 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Albumin - low | 26 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Calcium - low | 18 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Calcium - high | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Glucose - low | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Glucose - high | 9 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Magnesium - low | 14 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Magnesium - high | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Phosphorus - low | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Potassium - low | 8 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Potassium - high | 5 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Sodium - low | 14 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Sodium - high | 5 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Fracture | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Mood alteration - depression | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Restless leg | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Syncope | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Back pain | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Headache | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Neck pain | 3 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Tumor pain | 5 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Aspiration | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Bronchospasm/wheezing | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Cough | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dyspnea | 4 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Hypoxia | 2 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Voice changes/dysarthria | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Creatinine | 9 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Diuresis | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Dry eye syndrome | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Thrombosis | 1 participants |
| Arm 1 (Cetuximab) | Assess the Toxicity Profile for Standard of Care Cetuximab Given to Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | Trismus | 1 participants |
Secondary
Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Overall Survival With Cetuximab Therapy
Time frame: Every 8 weeks until death (approximately 5 years)
Population: The small dataset precluded an adequate analysis of overall survival relationships due to varying co-variates such as post-progression therapies, ECOG PS, co-morbidities.
Secondary
Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Time to Progression (TTP) With Cetuximab Therapy
Cetuximab was continued after cycle 1 in patients with disease control(PR/SD) by CT, even if the FDG-PET/CT showed PMD. Cetuximab was discontinued after cycle 1 in patients with progression by CT.
Time frame: Every 8 weeks until disease progression (up to 1 year)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm 1 (Cetuximab) | Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Time to Progression (TTP) With Cetuximab Therapy | 166 days |
| Stable Metabolic Disease (Overall PET Response) | Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Time to Progression (TTP) With Cetuximab Therapy | 105 days |
| Progressive Metabolic Disease (Overall PET Response) | Correlate the Overall Tumor Metabolic Response and Overall Anatomic Tumor Response and Clinical Examination Obtained at Baseline and After Eight Weeks of Treatment With Cetuximab to Time to Progression (TTP) With Cetuximab Therapy | 53 days |
Secondary
Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination
A generalization of McNemar's test was used to test for concordance of response(partial, stable or progression) by CT and by FDG-PET/CT.
Time frame: After 8 weeks of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Partial Response (overall CT response) | 1 participants |
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Stable Disease (overall CT response) | 9 participants |
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Progressive Disease (overall CT response) | 0 participants |
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Total (overall CT response) | 10 participants |
| Stable Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Stable Disease (overall CT response) | 5 participants |
| Stable Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Progressive Disease (overall CT response) | 0 participants |
| Stable Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Total (overall CT response) | 5 participants |
| Stable Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Partial Response (overall CT response) | 0 participants |
| Progressive Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Progressive Disease (overall CT response) | 7 participants |
| Progressive Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Stable Disease (overall CT response) | 5 participants |
| Progressive Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Total (overall CT response) | 12 participants |
| Progressive Metabolic Disease (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Partial Response (overall CT response) | 0 participants |
| Total (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Total (overall CT response) | 27 participants |
| Total (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Stable Disease (overall CT response) | 19 participants |
| Total (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Partial Response (overall CT response) | 1 participants |
| Total (Overall PET Response) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Progressive Disease (overall CT response) | 7 participants |
Secondary
Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination
Agreement in treatment decision using CT and FDG-PET/CT. Agreement in treatment decision occurred when tumor response by CT and FDG-PET/CT resulted in the same decision in treatment (continue cetuximab due to disease control or stop cetuximab due to progression). Disagreement in treatment decision occurred when tumor response assessment by CT and FDG-PET/CT resulted in different treatment decisions.
Time frame: After 8 weeks of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Treatment Agreement | 22 participants |
| Arm 1 (Cetuximab) | Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination | Treatment Disagreement | 5 participants |
Secondary
Determine the Overall Disease Control Rate by RECIST Criteria as Assessed by CT and Clinical Examination and to Determine the TTP and the OS With Cetuximab Therapy
Time frame: Every 8 weeks until death (approximately 5 years)
Population: This was not analyzed due to the lack of evidence-based medicine showing an overall survival benefit of cetuximab monotherapy in this type of cancer.
Secondary
Overall Anatomic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by CT Scan
Definitions of anatomic response by RECIST for CT scan included: complete response(CR)-disappearance of all target and non-target lesions and no new lesions; partial response(PR)-at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter, persistence of one or more non-target lesions, and no new lesions; stable disease (SD)-neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter since the treatment started, persistence of one or more non-target lesions, and no new lesions; progressive disease(PD)-at least a 20% increase in the sum of the longest diameter of target lesions recorded since the treatment started, appearance of one or more new lesions/unequivocal progression of existing non-target lesions.
Time frame: After 8 weeks of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Overall Anatomic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by CT Scan | Partial Response/Stable Disease | 20 participants |
| Arm 1 (Cetuximab) | Overall Anatomic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by CT Scan | Progressive Disease | 7 participants |
Secondary
Overall Best Anatomic Tumor Response Rate to Cetuximab Given Until Disease Progression as Assessed by RECIST Criteria Using CT & Clinical Examination
Time frame: Every 8 weeks until disease progression (up to 1 year)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Overall Best Anatomic Tumor Response Rate to Cetuximab Given Until Disease Progression as Assessed by RECIST Criteria Using CT & Clinical Examination | Partial Response | 1 participants |
| Arm 1 (Cetuximab) | Overall Best Anatomic Tumor Response Rate to Cetuximab Given Until Disease Progression as Assessed by RECIST Criteria Using CT & Clinical Examination | Stable Disease | 20 participants |
| Arm 1 (Cetuximab) | Overall Best Anatomic Tumor Response Rate to Cetuximab Given Until Disease Progression as Assessed by RECIST Criteria Using CT & Clinical Examination | Progressive Disease | 7 participants |
Secondary
Overall Tumor Metabolic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by FDG-PET/CT
Definitions of metabolic response by FDG-PET/CT included: complete metabolic response(CMR)-complete resolution of all metabolically active target and non-target lesions, and no new lesions; partial metabolic response(PMR)-20% or greater decrease in SUV of target lesions with or without decrease in number/size of non-target lesions, and no new lesions; progressive metabolic disease(PMD)-one or more new lesions, 20% or greater increase in SUV of target lesions and/or unequivocal increase in FDG activity of non-target lesions; and stable metabolic disease(SMD)-not qualifying as CMR, PMR, or PMD.
Time frame: After 8 weeks of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 (Cetuximab) | Overall Tumor Metabolic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by FDG-PET/CT | PMR/SMD | 15 participants |
| Arm 1 (Cetuximab) | Overall Tumor Metabolic Response to Eight Weeks of Scheduled Weekly Doses of Cetuximab as Assessed by FDG-PET/CT | PMD | 12 participants |